Literature DB >> 31412252

p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas.

Meng-Hsiung Hsieh1, Joshua H Choe2, Jashkaran Gadhvi1, Yoon Jung Kim1, Marcus A Arguez1, Madison Palmer1, Haleigh Gerold1, Chance Nowak1, Hung Do1, Simbarashe Mazambani1, Jordan K Knighton1, Matthew Cha1, Justin Goodwin3, Min Kyu Kang4, Ji Yun Jeong5, Shin Yup Lee6, Brandon Faubert7, Zhenyu Xuan8, E Dale Abel9, Claudio Scafoglio10, David B Shackelford10, John D Minna11, Pankaj K Singh12, Vladimir Shulaev13, Leonidas Bleris14, Kenneth Hoyt14, James Kim15, Masahiro Inoue16, Ralph J DeBerardinis17, Tae Hoon Kim1, Jung-Whan Kim18.   

Abstract

Squamous cell carcinoma (SCC), a malignancy arising across multiple anatomical sites, is responsible for significant cancer mortality due to insufficient therapeutic options. Here, we identify exceptional glucose reliance among SCCs dictated by hyperactive GLUT1-mediated glucose influx. Mechanistically, squamous lineage transcription factors p63 and SOX2 transactivate the intronic enhancer cluster of SLC2A1. Elevated glucose influx fuels generation of NADPH and GSH, thereby heightening the anti-oxidative capacity in SCC tumors. Systemic glucose restriction by ketogenic diet and inhibiting renal glucose reabsorption with SGLT2 inhibitor precipitate intratumoral oxidative stress and tumor growth inhibition. Furthermore, reduction of blood glucose lowers blood insulin levels, which suppresses PI3K/AKT signaling in SCC cells. Clinically, we demonstrate a robust correlation between blood glucose concentration and worse survival among SCC patients. Collectively, this study identifies the exceptional glucose reliance of SCC and suggests its candidacy as a highly vulnerable cancer type to be targeted by systemic glucose restriction.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GLUT1; SGLT2; SOX2; glucose restriction; ketogenic diet; p63; squamous cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31412252      PMCID: PMC7048935          DOI: 10.1016/j.celrep.2019.07.027

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  70 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response.

Authors:  Fuming Li; Xiangkun Han; Fei Li; Rui Wang; Hui Wang; Yijun Gao; Xujun Wang; Zhaoyuan Fang; Wenjing Zhang; Shun Yao; Xinyuan Tong; Yuetong Wang; Yan Feng; Yihua Sun; Yuan Li; Kwok-Kin Wong; Qiwei Zhai; Haiquan Chen; Hongbin Ji
Journal:  Cancer Cell       Date:  2015-04-30       Impact factor: 31.743

3.  ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.

Authors:  Srinivas Vinod Saladi; Kenneth Ross; Mihriban Karaayvaz; Purushothama R Tata; Hongmei Mou; Jayaraj Rajagopal; Sridhar Ramaswamy; Leif W Ellisen
Journal:  Cancer Cell       Date:  2016-12-29       Impact factor: 31.743

4.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.

Authors:  A Yang; M Kaghad; Y Wang; E Gillett; M D Fleming; V Dötsch; N C Andrews; D Caput; F McKeon
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

Review 5.  Squamous Cell Cancers: A Unified Perspective on Biology and Genetics.

Authors:  G Paolo Dotto; Anil K Rustgi
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

6.  Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.

Authors:  Yoichiro Mitsuishi; Keiko Taguchi; Yukie Kawatani; Tatsuhiro Shibata; Toshihiro Nukiwa; Hiroyuki Aburatani; Masayuki Yamamoto; Hozumi Motohashi
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

7.  SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.

Authors:  Hideo Watanabe; Qiuping Ma; Shouyong Peng; Guillaume Adelmant; Danielle Swain; Wenyu Song; Cameron Fox; Joshua M Francis; Chandra Sekhar Pedamallu; David S DeLuca; Angela N Brooks; Su Wang; Jianwen Que; Anil K Rustgi; Kwok-kin Wong; Keith L Ligon; X Shirley Liu; Jarrod A Marto; Matthew Meyerson; Adam J Bass
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

8.  NRF2 regulates serine biosynthesis in non-small cell lung cancer.

Authors:  Gina M DeNicola; Pei-Hsuan Chen; Edouard Mullarky; Jessica A Sudderth; Zeping Hu; David Wu; Hao Tang; Yang Xie; John M Asara; Kenneth E Huffman; Ignacio I Wistuba; John D Minna; Ralph J DeBerardinis; Lewis C Cantley
Journal:  Nat Genet       Date:  2015-10-19       Impact factor: 38.330

9.  p63 supports aerobic respiration through hexokinase II.

Authors:  Guiditta Viticchiè; Massimiliano Agostini; Anna Maria Lena; Mara Mancini; Huiqing Zhou; Lello Zolla; David Dinsdale; Gaelle Saintigny; Gerry Melino; Eleonora Candi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

Review 10.  Adenosquamous carcinoma of the lung.

Authors:  Chenghui Li; Hongyang Lu
Journal:  Onco Targets Ther       Date:  2018-08-14       Impact factor: 4.147

View more
  24 in total

Review 1.  Hyperinsulinaemia in cancer.

Authors:  Emily J Gallagher; Derek LeRoith
Journal:  Nat Rev Cancer       Date:  2020-09-09       Impact factor: 60.716

2.  OCT4, SOX2 and NANOG co-regulate glycolysis and participate in somatic induced reprogramming.

Authors:  Ying Ding; Xia Yuan; Yichen Zou; Jiachen Gao; Xianshuai Xu; Hongyan Sun; Qisheng Zuo; Yani Zhang; Bichun Li
Journal:  Cytotechnology       Date:  2022-03-17       Impact factor: 2.040

3.  CDK1 Promotes Epithelial-Mesenchymal Transition and Migration of Head and Neck Squamous Carcinoma Cells by Repressing ∆Np63α-Mediated Transcriptional Regulation.

Authors:  Huimin Chen; Ke Hu; Ying Xie; Yucheng Qi; Wenjuan Li; Yaohui He; Shijie Fan; Wen Liu; Chenghua Li
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

Review 4.  p63-related signaling at a glance.

Authors:  Matthew L Fisher; Seamus Balinth; Alea A Mills
Journal:  J Cell Sci       Date:  2020-09-11       Impact factor: 5.285

5.  Inducible knockout of ∆Np63 alters cell polarity and metabolism during pubertal mammary gland development.

Authors:  Sushil Kumar; Ajeya Nandi; Aakash Mahesh; Satrajit Sinha; Elsa Flores; Rumela Chakrabarti
Journal:  FEBS Lett       Date:  2019-12-17       Impact factor: 4.124

Review 6.  Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.

Authors:  Rachel J Perry; Gerald I Shulman
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

7.  Methionyl-tRNA synthetase and aminoacyl-tRNA synthetases interacting multi-functional protein-lacking exon 2 as potential diagnostic biomarkers for lung cancer.

Authors:  Taehee Kim; Kyosun Lee; Ji Hae Nahm; Eun Young Kim; Sang Hoon Lee; Yoon Soo Chang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11.

Authors:  Xinbo Wang; Yueqing Chen; Xudong Wang; Hongling Tian; Yanjin Wang; Jiali Jin; Zezhi Shan; Yu'e Liu; Zhenyu Cai; Xinyuan Tong; Yi Luan; Xiao Tan; Bing Luan; Xin Ge; Hongbin Ji; Xuejun Jiang; Ping Wang
Journal:  Cancer Res       Date:  2021-08-12       Impact factor: 12.701

Review 9.  Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review.

Authors:  Kristy T K Lau; Lui Ng; Jason W H Wong; Herbert H F Loong; Wendy W L Chan; Chi Ho Lee; Carlos K H Wong
Journal:  Rev Endocr Metab Disord       Date:  2021-07-17       Impact factor: 6.514

Review 10.  Designing Relevant Preclinical Rodent Models for Studying Links Between Nutrition, Obesity, Metabolism, and Cancer.

Authors:  Elaine M Glenny; Michael F Coleman; Erin D Giles; Elizabeth A Wellberg; Stephen D Hursting
Journal:  Annu Rev Nutr       Date:  2021-08-06       Impact factor: 11.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.